COVID-19: Clinical aspects and therapeutics responses

• Main Authors: Suliman Khan (Author), Ashaq Ali (Author), Hongwei Shi (Author), Rabeea Siddique (Author), Shabana (Author), Ghulam Nabi (Author), Junjie Hu (Author), Tiejun Wang (Author), Men Dong (Author), Wajid Zaman (Author), Guang Han (Author)
• Format: Book
• Published: Elsevier, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1319-0164; 10.1016/j.jsps.2020.06.022
• Keywords: COVID-19; Therapeutics; Mild symptoms; TCM; Recoveries; Therapeutics. Pharmacology; RM1-950
• Source: Saudi Pharmaceutical Journal, Vol 28, Iss 8, Pp 1004-1008 (2020)

COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5-7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs.